ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
95,047.99
-2.48%
S&P 500
5,867.08
0.00%
Dow Jones
42,342.24
0.00%
US Dollar vs Yen
156.497
-0.74%
Brent Oil
72.04
-0.48%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. BioCryst Pharmaceuticals Inc (BCRX)

  7. BioCryst Pharmaceuticals Inc (BCRX) ニュース

BCRX

BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:BCRX
日付受信時刻ニュースソース見出しコード企業名
2024/12/1806 : 22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/12/1806 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/12/1806 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/12/1806 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/12/1806 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/12/1706 : 35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/12/1406 : 23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/12/0506 : 15GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/12/0306 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/11/1816 : 00GlobeNewswire Inc.BioCryst Launches ORLADEYO® (berotralstat) in IrelandNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/11/0621 : 00GlobeNewswire Inc.BioCryst to Present at Upcoming Investor ConferencesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/11/0607 : 19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/11/0521 : 00GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/11/0421 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/11/0421 : 00GlobeNewswire Inc.BioCryst Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/10/2421 : 00GlobeNewswire Inc.BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/10/2120 : 00GlobeNewswire Inc.BioCryst to Report Third Quarter 2024 Financial Results on November 4NASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/10/1420 : 00GlobeNewswire Inc.BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/10/1020 : 00GlobeNewswire Inc.BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific MeetingNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/10/0320 : 00GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/10/0220 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/10/0220 : 00GlobeNewswire Inc.BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton SyndromeNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/09/3020 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/09/3020 : 00GlobeNewswire Inc.U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National StockpileNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/09/1720 : 00GlobeNewswire Inc.BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema AttacksNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/09/1101 : 09Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/09/0615 : 00GlobeNewswire Inc.BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin SymposiumNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/09/0520 : 00GlobeNewswire Inc.BioCryst Appoints Dr. Donald Fong Chief Medical OfficerNASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/09/0420 : 00GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
2024/09/0405 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:BCRX

最近閲覧した銘柄

PM
XAUUSD
Gold vs US Dollar
NYSE
JPM
JP Morgan Chase
AMEX
XLV
Health Care Select Sector
NYSE
DIS
Walt Disney
NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
USI
USTECH100
US Tech 100
USOTC
BNPQY
BNP Paribas (QX)
CCOM
US30
US 30
COIN
BTCUSD
Bitcoin
FX
USDJPY
US Dollar vs Yen
CCOM
US500
US 500
NASDAQ
AAPL
Apple
NYSE
AXP
American Express
COIN
AVAXUSD
Avalanche
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有